mivebresib   Click here for help

GtoPdb Ligand ID: 9117

Synonyms: ABBV-075 | ABBV075 | Example 36 [WO2013097601]
PDB Ligand
Compound class: Synthetic organic
Comment: Mivebresib (ABBV-075) is a potent orally available BET inhibitor [1]. BET inhibitors bind to the bromodomains of the bromodomain and extra-terminal motif (BET) proteins BRD2, BRD3, BRD4, and BRDT. This mechanism acts to prevent protein-protein interaction between BET proteins and acetylated histones and transcription factors. The action disrupts chromatin remodeling and inhibits expression of some growth-promoting genes which slows proliferation in susceptible tumours.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 101.57
Molecular weight 459.11
XLogP 5.44
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCS(=O)(=O)Nc1ccc(c(c1)c1cn(C)c(=O)c2c1cc[nH]2)Oc1ccc(cc1F)F
Isomeric SMILES CCS(=O)(=O)Nc1ccc(c(c1)c1cn(C)c(=O)c2c1cc[nH]2)Oc1ccc(cc1F)F
InChI InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3
InChI Key RDONXGFGWSSFMY-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 1 clinical trial evaluating the safety and pharmacokinetics of mivebresib (ABBV-075) in cancer patients (NCT02391480) has been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02391480 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Phase 1 Interventional AbbVie